Literature DB >> 7595218

Presentation of a self-peptide for in vivo tolerance induction of CD4+ T cells is governed by a processing factor that maps to the class II region of the major histocompatibility complex locus.

E V Fedoseyeva1, R C Tam, P L Orr, M R Garovoy, G Benichou.   

Abstract

Self-proteins are regularly processed for presentation to autoreactive T cells in association with both class I and class II major histocompatibility complex (MHC) molecules. The presentation of self-peptides plays a crucial role in the acquisition of T cell repertoire during thymic selection. We previously reported that the self-MHC class I peptide Ld 61-80 was immunogenic in syngeneic B10.A mice (H-2a). We showed that despite its high affinity for self-MHC class II molecules, Ld 61-80 peptide failed to induce elimination of autoreactive CD4+ T cells, presumably due to incomplete processing and presentation in the B10.A's developing thymus (cryptic-self peptide). In this report, we showed that the cryptic phenotype was not an intrinsic property of the self-peptide Ld 61-80 since it was found to be naturally presented and subsequently tolerogenic in BALB/c mice (H-2d) (dominant self-peptide). In addition, the self-peptide Ld 61-80 was found to be immunogenic in different H-2a mice while it was invariably tolerogenic in H-2d mice regardless of their background genes. We observed that Ld 61-80 bound equally well to H-2d and H-2k MHC class II molecules. Also, no correlation was found between the quantity of self-Ld protein and the tolerogenicity of Ld 61-80. Surprisingly, Ld 61-80 was not naturally presented in (H-2d x H-2a) F1 mice, indicating that the H-2a MHC locus contained a gene that impaired the presentation of the self-peptide. Analyses of T cell responses to the self-peptide in several H-2 recombinant mice revealed that the presentation of Ld 61-80 was controlled by genes that mapped to a 170-kb portion of the MHC class II region. This study shows that (a) endogenously processed self-peptides presented by MHC class II molecules are involved in shaping the CD4+ T cell repertoire in the thymus; (b) The selection of self-peptides for presentation by MHC class II molecules to nascent autoreactive T cells is influenced by nonstructural MHC genes that map to a 170-kb portion of the MHC class II region; and (c) the MHC locus of H-2a mice encodes factors that prevent or abrogate the presentation by MHC class II molecules of the self-peptide Ld 61-80. These findings may have important implications for understanding the molecular mechanisms involved in T cell repertoire acquisition and self-tolerance induction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7595218      PMCID: PMC2192203          DOI: 10.1084/jem.182.5.1481

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  38 in total

1.  Sequence analysis of peptides bound to MHC class II molecules.

Authors:  A Rudensky; P Preston-Hurlburt; S C Hong; A Barlow; C A Janeway
Journal:  Nature       Date:  1991-10-17       Impact factor: 49.962

2.  A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC.

Authors:  R Glynne; S H Powis; S Beck; A Kelly; L A Kerr; J Trowsdale
Journal:  Nature       Date:  1991-09-26       Impact factor: 49.962

3.  Subunit of the '20S' proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex.

Authors:  V Ortiz-Navarrete; A Seelig; M Gernold; S Frentzel; P M Kloetzel; G J Hämmerling
Journal:  Nature       Date:  1991-10-17       Impact factor: 49.962

4.  Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes.

Authors:  M G Brown; J Driscoll; J J Monaco
Journal:  Nature       Date:  1991-09-26       Impact factor: 49.962

Review 5.  The transporters associated with antigen presentation.

Authors:  A Townsend; J Trowsdale
Journal:  Semin Cell Biol       Date:  1993-02

6.  Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes.

Authors:  P Kisielow; H Blüthmann; U D Staerz; M Steinmetz; H von Boehmer
Journal:  Nature       Date:  1988-06-23       Impact factor: 49.962

7.  Cellular and peptide requirements for in vitro clonal deletion of immature thymocytes.

Authors:  K Iwabuchi; K Nakayama; R L McCoy; F Wang; T Nishimura; S Habu; K M Murphy; D Y Loh
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

8.  Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen.

Authors:  P V Lehmann; T Forsthuber; A Miller; E E Sercarz
Journal:  Nature       Date:  1992-07-09       Impact factor: 49.962

9.  Direct evidence for functional self-protein/Ia-molecule complexes in vivo.

Authors:  R G Lorenz; P M Allen
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

10.  Major histocompatibility complex class II-restricted presentation of an internally synthesized antigen displays cell-type variability and segregates from the exogenous class II and endogenous class I presentation pathways.

Authors:  G E Loss; C G Elias; P E Fields; R K Ribaudo; M McKisic; A J Sant
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

View more
  3 in total

Review 1.  Self determinant selection and acquisition of the autoimmune T cell repertoire.

Authors:  G Benichou; R C Tam; P I Orr; M R Garovoy; E V Fedoseyeva
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

2.  Indirect recognition of donor HLA-DR peptides in organ allograft rejection.

Authors:  Z Liu; A I Colovai; S Tugulea; E F Reed; P E Fisher; D Mancini; E A Rose; R Cortesini; R E Michler; N Suciu-Foca
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

3.  Dual effects of the alloresponse by Th1 and Th2 cells on acute and chronic rejection of allotransplants.

Authors:  Ben M Illigens; Akira Yamada; Natalie Anosova; Victor M Dong; Mohamed H Sayegh; Gilles Benichou
Journal:  Eur J Immunol       Date:  2009-11       Impact factor: 5.532

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.